Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press47910.17650/1994-4098-2016-12-1-68-72ГИНЕКОЛОГИЯ. ОБЗОРAltered strategy in the treatment of patients with recurrent ovarian cancer. According to the proceedings of the 5th International Conference on Gynecologic Oncology hosted by the MD Anderson Cancer Center (Madrid, Spain, 24–26 February 2016)Изменение стратегии в лечении больных с рецидивами рака яичников По материалам 5-й Международной конференции по гинекологической онкологии, проводимой MD Anderson Cancer Center (Мадрид, Испания, 24–26 февраля 2016 г.)KedrovaA. G.КедроваА. Г.
Russian Federation
kedrova.anna@gmail.comDepartment of Oncology, Federal Research and Clinical Center for Specialized Medical Cares and Medical Technologies, Federal Biomedical Agency of RussiaОнкологическое отделение ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства»28 Orekhovyy Boulevard, Moscow, 115682, RussiaРоссия, 115682, Москва, Ореховый бульвар, 28Department of Obstetrics and Gynecology, Institute for Advanced Training, Federal Biomedical Agency of Russiaкафедра акушерства и гинекологии ФГБОУ ДПО «Институт повышения квалификации Федерального медико-биологического агентства»91 Volokolamskoe Shosse, Moscow, 125371, RussiaРоссия, 125371, Москва, Волоколамское шоссе, 910606201612168720606201606062016https://ojrs.abvpress.ru/ojrs/article/view/479

The paper highlights main areas in the development of European oncology care to patients with malignant ovarian neoplasms. It discusses the major issues considered at the 5th Annual Meeting of Oncologists on Arrangement of Anticancer Therapy into the Era of Personalized Therapy hosted by the MD Anderson Cancer Center.

В статье освещены основные направления развития европейской онкологической помощи больным злокачественными опухолями яичников. Обсуждены главные вопросы, рассмотренные на 5-й конференции по гинекологической онкологии «Выстраивание противоракового лечения в эру персонализированной терапии», проводимой MD Anderson Cancer Center.

malignant ovarian neoplasmschemotherapyrecurrencesзлокачественные новообразования яичниковхимиотерапиярецидивы1. WHO classification of tumours of female reproductive organs. Ed. by R.J. Kurman. 2014. 2. Burton E.R., Brady M., Homesley H.D. et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2016;140(1):48–52.WHO classification of tumours of female reproductive organs. Ed. by R.J. Kurman. 2014. 2. Burton E.R., Brady M., Homesley H.D. et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2016;140(1):48–52.3. Homesley H.D. GOG 0187: A Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First Line or Second Line Therapy.Homesley H.D. GOG 0187: A Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First Line or Second Line Therapy.4. Sharad Ghamand GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary. Cancer 2014;120(3):344–51.Sharad Ghamand GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary. Cancer 2014;120(3):344–51.5. Lilian Gien. RT1508: A phase II evaluation of enzalutamide (inhibition of CYP17) for recurrent sex cord-stromal ovarian tumors.Lilian Gien. RT1508: A phase II evaluation of enzalutamide (inhibition of CYP17) for recurrent sex cord-stromal ovarian tumors.6. Lamm W., Schiefer A., Nöbauer I.M. et al. Aromatase inhibitor therapy as effective rescue in a patient with tamoxifen-refractory metastatic granulosa cell tumor of the ovary. J Clin Oncol 2016;34(5):e31–3.Lamm W., Schiefer A., Nöbauer I.M. et al. Aromatase inhibitor therapy as effective rescue in a patient with tamoxifen-refractory metastatic granulosa cell tumor of the ovary. J Clin Oncol 2016;34(5):e31–3.7. van Meurs H.S., Schuit E., Horlings H.M. et al. Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecol Oncol 2014;134(3):498–504.van Meurs H.S., Schuit E., Horlings H.M. et al. Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecol Oncol 2014;134(3):498–504.8. Chiang S., Staats P.N., Senz J. et al. FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors. Am J Surg Pathol 2015;39(5):618–23.Chiang S., Staats P.N., Senz J. et al. FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors. Am J Surg Pathol 2015;39(5):618–23.9. Heravi-Moussavi A., Anglesio M., Cheng S.W. et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012;366(3):234–42.Heravi-Moussavi A., Anglesio M., Cheng S.W. et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012;366(3):234–42.10. Gershenson D.M. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book 2013.Gershenson D.M. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book 2013.11. Gershenson D.M., Bodurka D.C., Lu K.H. et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol 2015;33(24):2675–82.Gershenson D.M., Bodurka D.C., Lu K.H. et al. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol 2015;33(24):2675–82.12. Callegaro-Filho D., Gershenson D.M., Nick A.M. et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 patients. Gynecol Oncol 2016;140(1):53–7.Callegaro-Filho D., Gershenson D.M., Nick A.M. et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 patients. Gynecol Oncol 2016;140(1):53–7.13. Gourley C., McCavigan A., Perren T. et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Presented at: 2014 ASCO Annual Meeting; May 30–June 3, 2014; Chicago, Illinois. Abstr. 5502.Gourley C., McCavigan A., Perren T. et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Presented at: 2014 ASCO Annual Meeting; May 30–June 3, 2014; Chicago, Illinois. Abstr. 5502.14. Murai J., Huang S.Y., Das B.B. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72(21):5588–99.Murai J., Huang S.Y., Das B.B. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72(21):5588–99.15. Audeh M.W., Carmichael J., Penson R.T. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245–51.Audeh M.W., Carmichael J., Penson R.T. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245–51.